RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62

بيومارين فارماسيوتيكال

BioMarin Pharmaceutical Inc.

BMRN

0.00

RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ: BMRN) with a Sector Perform and lowers the price target from $66 to $62.